Skip to main content
Figure 2 | Journal of Hematology & Oncology

Figure 2

From: Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application

Figure 2

Induction of the TP53 target genes CDKN1A , BAX and PUMA in CLL cases of the training cohort with a TP53 mutated status ( TP53mut/delor TP53mut/wtgenotypes) or a TP53 wild type status evaluated by direct sequencing. A) Box-and-whisker plots show data obtained by qRT-PCR evaluation of CDKN1A, BAX and PUMA expression levels in untreated or Nutlin-3 treated samples of CLL cases of the training cohort with a mutated or with an unmutated TP53 status. The corresponding p value (Studentā€™s t-test) is reported. B) Histograms represent Nutlin-3 treated/untreated mean fold induction in TP53 wild type (white bar) and TP53 mutated (TP53mut/del or TP53mut/wt genotypes, grey bar) CLL cases. Reported p values refer to Studentā€™s t-test. Error bars represent SD.

Back to article page